Company intelligence / Profile preview

RetinaRisk

Ownership: Private
Development stage: Other

Overview

The clinically validated RetinaRisk algorithm has been used in over 25,000 patients across multiple continents. It accurately calculates the individualized risk of developing sight-threatening diabetic retinopathy and has demonstrated effectiveness in reducing unnecessary screening visits while focusing resources on high-risk patients. The solution has been integrated into clinical workflows and AI-based grading systems[1][2][5].

Therapeutic areas: Ophthalmology
Modalities: Device (app/software)Non-pharmacological therapy
Industry: Medical Imaging

Partnerships

Remidio Innovative Solutions (AI-driven DR screening integration in India and Iceland)[3][4]University of Iceland[2]Landspitali University Hospital[2]

Beyond the preview

Go deeper on RetinaRisk.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetinaRisk.

Explore the full profile